As a source of human suffering, a barrier to workplace productivity, a burden on families and a driver of medical costs, mental illness amounts to an unparalleled public health crisis. Fortunately, there’s an abundance of smart thinking on how to improve the lives of people who struggle with major depression, schizophrenia, bipolar disorder, and other serious conditions.
In this report, inVentiv Health has synthesized some of this analysis, with particular attention to the recommendations, strategies and aspirations of patient advocacy groups. We have also collected insights from pharmaceutical companies, payers and other key stakeholders. Amidst great uncertainty in the healthcare environments of the US and Europe, inVentiv Health hopes to shine a light on unique challenges posed by mental health disorders and some possible solutions.
During Biotech Showcase 2017 David Thompson, Senior Vice President for Real-World Evidence Consulting, inVentiv Health moderated a panel of experts through a discussion on real-world evidence. The panel discussed how real-world insights from patients and other stakeholders can lead to better drug development, improved patient compliance and ultimately better outcomes.
GSW and inVentiv Health Communications’ 6th installment of the trend report series is a product of global collaboration. Over 100 trendspotters from around the world worked to curate the clues, examples, stories and big ideas that are shaping communications, healthcare, digital experience, and consumer expectations for 2017.
New research from GSW, inVentiv Health PR Group and PALIO indicates that millennial physicians are redefining the patient-physician relationship. Four out of five millennial physicians (81%) believe that their millennial patients require a different relationship with their doctors than older patients. And 66% of those Generation Y docs are changing their approach according to the age of the patient they’re seeing. This report outlines how millennial doctors prefer a collaborative approach to nearly all aspects of their practice, and provides advice on how pharma brands can engage more effectively with this key physician audience.
At a rapid pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases. These relationships are bringing new value to both sides but raising challenges as well – patient groups are seeking earlier engagement, greater access, and companies continue to push for progress.
The latest report from inVentiv Health Public Relations Group – based on several months of extensive research and in-depth interviews – takes a deeper look at the dynamics currently reshaping collaboration in rare disease and how future roles will be defined.
inVentiv Health advertising agency, GSW, is looking ahead to 2016 in the fifth annual trends series. The series is fueled by clues, examples and big ideas collected by more than 70 trend watchers from around the world.
There's no question that 2014 was a banner year for dealmaking: $355 billion in total transactions, including $53 billion in partnering deals, $16.5 billion in venture investments and 133 IPOs. But could it be a case of too much of a good thing? What therapeutic areas or technologies will offer the best opportunity this year? How can the smaller biotech company best position itself to reap the rewards of a bull market – and minimize risk of being thrown?
For answers to these questions and more, read Dealmakers’Intentions 2015 from inVentiv Health consulting firm, Campbell Alliance. Unveiled at the 2015 BIO International Conference, the survey suggests that 2015 will set a new record for mergers and acquisitions and licensing of biopharmaceutical assets. The results also revealed early signs of a potential slow-down in licensing of assets.
This is the seventh year that Campbell Alliance has surveyed dealmakers to provide a forward-looking glimpse of what the rest of the year will hold and identify areas of greatest opportunities for buyers and sellers.
Oncology is one of the most complex and fast-changing therapeutic areas. This series examines critical topics in oncology drug development and commercialization.
inVentiv Health was on the floor of American Society of Clinical Oncology (ASCO) meeting, reporting live for Clinical Leader. Read our insights from the annual meeting of the world's leading cancer experts - from the latest scientific breakthroughs to discussions on the challenges pharmaceutical companies face in bringing novel oncology therapies to market.
Immune Checkpoint Inhibitors (ICIs) - novel agents that activate the human immune response against antigens expressed on tumor cells - pose challenges for clinical trial researchers. Due to the complexity of managing these trials and the fact that this new drug class is not well known or understood within the oncology community, clinical trials investigating ICIs require special strategies to be successful. This paper explores several issues and makes recommendations.
Dramatic changes in U.S. healthcare over the last few years have forced a rethinking of all kinds of stakeholder relationships, including the partnerships biopharmaceutical companies have formed with groups representing patients and families. The rules of engagement are changing. inVentiv Health interviewed dozens of patient advocacy groups, including those in oncology, to understand how they view the evolution, what they seek from their pharma partners and what companies need to keep in mind as they navigate these new waters.
As our population ages and medical advances increase life expectancy, drug developers are facing an emerging gap in clinical research: lack of evidence to guide treatment decisions for people over 65. Almost a year ago, the Food and Drug Administration held a public meeting asking for suggestions on how to include more older people in clinical trials. Since then, a number of experts around the world have expressed similar concern. The most
Despite the seriousness of diagnosis – or perhaps because of it – only three percent of adult patients with cancer participate in clinical trials. In a study of 500 trials, 60 percent in Phase III failed to achieve minimum patient enrollment. With 800 new medicines and vaccines targeting cancer in the pipeline, the problem is immense. And if patient enrollment is difficult, forecasting is even more so. Feasibility experts from inVentiv Health look at how combining data with sophisticated informatics tools allows sponsors to evaluate feasibility plans and timelines with a high degree of precision, leading to greater trial predictability, shorter timelines and meaningful cost savings.
Branding means a lot of different things to a lot of different people, but in its simplest form, a name is the face of a brand. Just as people have names – something we're recognized by and called – so do pharmaceutical brands. Over time a strong brand name can grow to be synonymous with a number of things like quality, reliability or clarity. This whitepaper focuses on the practice of naming an oncology asset and how this process has evolved over the years.
A column from a recent edition of CenterWatch Weekly looks at the rise of breakthrough immunotherapy science. It traces the roots of a pivotal cancer organization that is now at the center of some of the most exciting advances in cancer treatment, the Cancer Research Institute. The nonprofit drug development incubator group breaks down silos between researchers and biopharmaceutical companies to speed therapies to patients.
“To realize the potential of our technology and move quickly into market, we sought a partner that could execute every phase and function in commercialization – and inVentiv was the obvious choice.”– Chief Executive Officer, Aprecia
"I was very impressed with the level of industry knowledge...it was a pleasure to work with the team."– Client at Pfizer
"I felt inVentiv was a company that could read between the lines and see the bigger picture of what we’re trying to achieve – from a long-term point of view."– Vice President Sales, Top 10 Pharma
"inVentiv will become even more important to us in the future as we face margin compression, patent cliffs, and the changes in healthcare."– Vice President Sales, Top 10 Pharma
"After an extensive global review of potential clinical research organizations, we selected the broad-scale inVentiv platform as an important differentiator for our program."– President and CEO, Advaxis